Tufts University Release: Novel Bioactive Peptides Promote Wound Healing In Vivo
BOSTON, Feb. 24, 2012 /PRNewswire-USNewswire/ -- Researchers have combined bioactive peptides to successfully stimulate wound healing. The in vitro and in vivo study, published today in PLoS ONE, demonstrates that the combination of two peptides stimulates the growth of blood vessels and promotes re-growth of tissue. Further development of these peptides could lead to a new treatment for chronic and acute wounds.
The team tested a newly-created peptide, UN3, in pre-clinical models aimed to simulate impaired wound healing as is seen in patients with peripheral vascular diseases or uncontrolled diabetes. The peptide led to a 50% increase in blood vessel wall development, a 250% increase in growth of blood vessels, and a 300% increase in cell migration in response to the injury.
"Using double-blinded in vivo experiments, we then applied the wound-healing peptide UN3 with a peptide created during a previous study, named comb1. We found that, together, the two out-performed all control groups, including the only FDA-approved growth factor-containing drug for treating diabetic wounds, becaplermin," said first author, Tatiana Demidova-Rice, Ph.D., now a graduate of the cell, molecular and developmental biology program at the Sackler School of Graduate Biomedical Sciences.
In December 2010, Herman and Demidova-Rice identified several peptides from a Clostridium histolyticum collagenase treatment of bio-synthesized extracellular matrix. The investigators then went on to cull key peptides and, from these, they created the peptide, comb1, possessing several strategic features, including its ability to stimulate angiogenesis by increasing blood vessel growth by 200% in vitro.
The second wound-healing peptide, UN3, identified in the current study, was created and modified from two naturally occurring peptides that are normally present in trace amounts and found in human platelet-rich plasma.
"The confirmation that these peptides could act synergistically to improve human wound healing moves our research one significant step
closer to clinical application. We hope that someday soon, we may be able to help transform the way in which wound care is being delivered in civilian and combat settings," said Ira Herman, Ph.D., professor of molecular physiology and pharmacology at Tufts University School of Medicine. Professor Herman is director, molecular and cellular physiology graduate program at the Sackler School of Graduate Biomedical Sciences and director, Center for Innovations in Wound Healing Research, Tufts University.
"The wound-healing peptides should also prove strategic as we continue developing 'smart' devices or fully-vascularized living tissue constructs for burn patients or those patients suffering with diabetic plantar or venous stasis ulcers. Clinical trials using the peptides will be the next step," Herman continued. Tufts University has filed patent applications related to the wound-healing peptides.
Tufts Center for Innovations in Wound Healing Research brings together experts from Tufts' medical, dental, veterinary and engineering schools, as well as Tufts Medical Center and local research institutes with a focus on creating innovative wound healing therapeutics as well as fully-vascularized organ constructs for personalized regenerative medicine.
Demidova-Rice is now at the Edwin L. Steele Laboratory for Tumor Biology in the department of Radiation Oncology at Massachusetts General Hospital. Additional authors include Lindsey Wolf, BS, formerly a research assistant at TUSM, now a graduate student working towards a Ph.D. degree in the department of molecular genetics and microbiology at the University of Texas at Austin; Jeffry Deckenback, Ph.D., who was a postdoctoral fellow in the Herman lab while the work was being carried out; and Michael R. Hamblin, Ph.D., a principal investigator at the Wellman Center for Photomedicine at Massachusetts General Hospital and associate professor in the department of dermatology at Harvard Medical School.
This research was supported in part by grants # EY15125 and # EY19533 from the National Eye Institute, part of the National Institutes of
Health, and Wound Care Partners, LLC.
Demidova-Rice TN, Wolf L, Deckenback J, Hamblin MR, Herman IM. PLoS ONE. "Human Platelet-Rich Plasma- and Extracellular Matrix-Derived Peptides Promote Impaired Cutaneous Would Healing In Vivo." Published February 23, 2012, doi:10.1371/journal.pone.0032146.
About Tufts University School of Medicine and the Sackler School of Graduate Biomedical Sciences
Tufts University School of Medicine and the Sackler School of Graduate Biomedical Sciences at Tufts University are international leaders in innovative medical education and advanced research. The School of Medicine and the Sackler School are renowned for excellence in education in general medicine, biomedical sciences, special combined degree programs in business, health management, public health, bioengineering and international relations, as well as basic and clinical research at the cellular and molecular level. Ranked among the top in the nation, the School of Medicine is affiliated with six major teaching hospitals and more than 30 health care facilities. Tufts University School of Medicine and the Sackler School undertake research that is consistently rated among the highest in the nation for its effect on the advancement of medical science.
This news release was issued on behalf of Newswise. For more information, visit http://newswise.com.
SOURCE Tufts University